Australia Age-Related Macular Degeneration Market | Worth USD 239.47 Million 2026-2034

Market Overview

The Australia age-related macular degeneration market reached USD 209.12 Million in 2025 and is projected to grow to USD 239.47 Million by 2034. The forecast period spans from 2026 to 2034 with an anticipated CAGR of 1.52%. Key growth drivers include Australia's rapidly aging population, enhanced government reimbursement policies, and advancements in artificial intelligence enabling early diagnosis and disease monitoring. These factors collectively boost treatment accessibility and expand the market share. For more detailed information, visit the Australia Age-Related Macular Degeneration Market

How AI is Reshaping the Future of Australia Age-Related Macular Degeneration Market

• Advanced deep learning algorithms analyze optical coherence tomography scans and color fundus photographs with diagnostic accuracy comparable or superior to human experts.

• AI models predict disease progression, optimize treatment intervals for anti-VEGF injections, and enable early automated screening programs, enhancing disease management.

• AI-enabled remote monitoring addresses geographic disparities by facilitating access to quality eye care in rural and remote Australian populations.

• Telemedicine platforms incorporating AI diagnostic tools enable preliminary AMD screening in primary care or community health centers, improving early specialist referrals.

• A qualitative study by UNSW Sydney with 37 stakeholders revealed increasing acceptability and anticipated fee-for-service models for AI-driven remote monitoring of neovascular AMD.

• Successful AI integration requires algorithm validation, transparent system communication, ongoing clinical oversight, and robust data governance to ensure ethical deployment.

Grab a sample PDF of this report: https://www.imarcgroup.com/australia-age-related-macular-degeneration-market/requestsample

Market Growth Factors

The Australian market is propelled by a rapidly aging population, reshaping healthcare demands for age-related conditions like macular degeneration, which affects about 1.25 million Australians over 50. This figure is expected to rise to 1.7 million as more enter higher-risk age groups. The Australian Bureau of Statistics projects that by 2066, nearly 25% of Australians will be aged 65 or older, significantly increasing the at-risk demographic. This demographic shift drives demand for diagnostic services, anti-VEGF therapies, and specialized ophthalmic care, prompting healthcare systems to expand capacity and implement comprehensive eye screening programs across metropolitan and regional areas.

Government policies and reimbursement schemes strongly support market expansion. The National Strategic Action Plan for Macular Disease launched in 2022 coordinates national efforts to improve service delivery, research funding, and patient support, notably enhancing diagnostic availability in rural and underserved regions. Meanwhile, the Pharmaceutical Benefits Scheme subsidizes anti-VEGF drugs like Lucentis, Eylea, Beovu, and Vabysmo, reducing out-of-pocket costs for patients and improving treatment affordability. Ongoing collaborations between federal and state health departments aim to expand hospital eye injection clinics to manage rising demand while maintaining high treatment standards.

Artificial intelligence technologies fundamentally transform AMD diagnosis and management, offering accuracy comparable to expert clinicians through machine learning analysis of retinal imaging. AI helps predict disease progression, optimize injection intervals, and support personalized regimens, decreasing unnecessary visits and improving healthcare resource allocation. AI-based remote screening and monitoring particularly benefit Australia's rural and remote populations by mitigating geographic healthcare disparities. However, successful integration depends on validated algorithms, transparency in limitations, human clinical oversight, and strong data governance frameworks ensuring ethical and privacy-compliant use.

Browse the full report with TOC and list of figures: https://www.imarcgroup.com/australia-age-related-macular-degeneration-market

Market Segmentation

Analysis by Product:

• Eylea

• Lucentis

• Beovu

• Others

Analysis by Disease Type:

• Wet Age-related Macular Degeneration

• Dry Age-related Macular Degeneration

Analysis by Region:

• Australia Capital Territory & New South Wales

• Victoria & Tasmania

• Queensland

• Northern Territory & Southern Australia

• Western Australia

Key Players

• BenoBio

Recent Developement & News

• July 2025: The Australian government reinforced its commitment to combating macular disease by expanding the National Strategic Action Plan, resulting in improved diagnostic service availability in rural and underserved regions, thereby increasing early detection and treatment accessibility.

• March 2025: BenoBio commenced a Phase I dose-escalation clinical trial of BBRP11001 targeting neovascular AMD patients resistant to conventional anti-VEGF therapies. This initiative reflects pharmaceutical innovation responding to unmet treatment needs and growing patient demand.

• October 2025: Pharmaceutical Benefits Scheme updates continued to subsidize anti-VEGF medications, ensuring affordability for both concession and general beneficiaries despite potential private insurance coverage changes, supporting sustained patient adherence and broad market growth.

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Ask an analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=44015&flag=C

Contact Us

IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201-971-6302

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.